Public disclosure of the monthly exercise status for the 58th and 66th stock acquisition rights. In the target month, exercises were 0 shares; unexercised rights are 120,510 shares for the 66th and 20,000 shares for the 58th. In addition, disclosures regarding the cancellation plan for the 58th, 66th, and 67th stock acquisition rights and the buyback agreement are referenced.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBio Pharmaceuticals Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4582-20260831-01.pdf","jir_short_summary":"Public disclosure of the monthly exercise status for the 58th and 66th stock acquisition rights. In the target month, exercises were 0 shares; unexercised rights are 120,510 shares for the 66th and 20,000 shares for the 58th. In addition, disclosures regarding the cancellation plan for the 58th, 66th, and 67th stock acquisition rights and the buyback agreement are referenced.","jir_summary":"### Section 1\nThis notice covers the exercise status for the 58th and 66th stock acquisition rights for August 2026 and future handling. In the target month, there were 0 actual exercises, and the total unexercised rights are 120,510 shares for the 66th and 20,000 shares for the 58th. In addition, disclosures regarding the cancellation plan for the 58th, 66th, and 67th stock acquisition rights and related buyback contracts are mentioned.\n\n### Section 2\nAs a recent development, on August 17, 2026, debt facility-related issuances and buyback contracts were finalized, and the remaining 58th and 66th stock acquisition rights are planned to be cancelled on September 1, 2026. For the 67th stock acquisition right with an exercise price adjustment clause, as a principle of the buyback contract design, it cannot be exercised until August 13, 2027, and the monthly disclosure for this has been omitted.","jir_financial_highlights":"Unexercised stock acquisition rights (66th): 120,510 shares (0% exercise)\nUnexercised stock acquisition rights (58th): 20,000 shares (0% exercise)\nTotal issued (66th): 200,000 units (0%)\nTotal issued (58th): 20,000 units (0%)","jir_category":"","jir_hashtags":"#SymBioPharmaceuticals Limited \u043f\u0443\u0431\u043b\u0438\u043a\u0430, #StockAcquisitionRight, #DisclosureUpdate","jir_key_figures":"Total issued for 66th stock acquisition rights: 200,000 units\nUnexercised (66th): 120,510 shares\nUnexercised (58th): 20,000 shares","jir_meta_title":"[SymBio Pharmaceuticals] Monthly Exercise Status and Cancellation Plan for Stock Acquisition Rights | August 2026","jir_meta_description":"Disclosure of August 2026 monthly exercise status, unexercised shares, and cancellation plan for the 58th and 66th stock acquisition rights of SymBio Pharmaceuticals. Exercises: 0; outline of cancellation date and related buyback contracts.","jir_og_title":"[SymBio Pharmaceuticals] Monthly Exercise Status and Cancellation Plan for Stock Acquisition Rights","jir_og_description":"SymBio Pharmaceuticals discloses August status for the 58th and 66th stock acquisition rights. Current exercises: 0; unexercised shares: 120,510 and 20,000. Summary of cancellation date and related contracts.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-108800","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n